Muscle Spasticity Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others), By Route of Administration (Oral, Intramuscular, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.65 Billion
CAGR (2026-2031)	6.78%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America
Market Size (2031)	USD 5.41 Billion

Market Overview

The Global Muscle Spasticity Market will grow from USD 3.65 Billion in 2025 to USD 5.41 Billion by 2031 at a 6.78% CAGR. The global muscle spasticity market comprises pharmaceutical interventions and medical devices designed to alleviate involuntary muscle contractions associated with central nervous system disorders. Market expansion is fundamentally supported by the rising prevalence of chronic conditions such as cerebral palsy and stroke which necessitate consistent therapeutic management to improve patient mobility. According to the Multiple Sclerosis International Federation, in 2024, the updated Atlas of MS data indicated that there are approximately 2.9 million people living with multiple sclerosis worldwide. This growing patient population requires sustained antispasmodic treatments and creates a stable demand for effective therapeutic solutions.

However, a substantial challenge hindering broader market progression is the prohibitive cost of advanced treatments including botulinum toxin injections and intrathecal baclofen pumps. High expenses coupled with inadequate reimbursement frameworks in emerging economies limit patient access to these essential therapies. This financial barrier restricts the adoption of premium care options and forces many healthcare providers to rely on generic oral medications with lower efficacy profiles, thereby impeding the overall revenue potential in developing regions.

Key Market Drivers

The rising prevalence of chronic neurological disorders serves as a primary catalyst for market growth, specifically due to the high incidence of spasticity following central nervous system insults. Conditions such as stroke and traumatic brain injuries disrupt neural signaling, creating an urgent requirement for long-term management strategies to prevent permanent muscle contractures. According to the World Health Organization, March 2024, in the 'Global burden of neurological disorders' study, neurological conditions were found to affect approximately 3.4 billion individuals globally, positioning them as the leading cause of disability. This massive patient volume ensures sustained demand for therapeutic interventions. Highlighting the specific burden of trauma, according to the National Spinal Cord Injury Statistical Center, in 2024, the prevalence of spinal cord injuries in the United States was estimated to be approximately 305,000 cases, a demographic heavily reliant on consistent antispasmodic care.

The growing adoption of botulinum toxin injectables acts as a second major driver, shifting clinical preference from systemic oral medications to targeted focal therapies. These biologicals offer precise muscle relaxation with fewer systemic side effects, prompting increased utilization by specialists for refractory spasticity. This trend toward high-value biologic treatments is evidenced by recent financial performance in the sector. According to AbbVie, October 2024, in the 'Third-Quarter 2024 Financial Results', global net revenues for its therapeutic botulinum toxin portfolio reached $848 million for the quarter. This revenue growth underscores the expanding role of injectable neurotoxins as a standard of care, directly boosting the value proposition of the overall market.

Download Free Sample Report

Key Market Challenges

The prohibitive cost of advanced therapeutic interventions, specifically botulinum toxin injections and intrathecal baclofen pumps, constitutes a primary restraint on the global muscle spasticity market. These premium treatment modalities require significant financial investment from both healthcare systems and patients. In many regions, reimbursement policies are insufficient to cover the high expenses associated with these biologics and medical devices. Consequently, healthcare providers are frequently compelled to prescribe generic oral medications that are more affordable but often less effective in managing severe symptoms.

This financial disparity limits market penetration in developing economies where out-of-pocket expenditure is common. The economic burden of the underlying conditions further exacerbates this issue, leaving limited resources for expensive spasticity management. According to the World Stroke Organization, in 2024, the global economic impact of stroke was estimated to be approximately 890 billion dollars annually. Such substantial baseline healthcare costs make it difficult for payers to approve additional high-cost spasticity therapies. This economic pressure directly reduces the adoption rates of advanced solutions, thereby restricting the total revenue generation and growth potential of the market.

Key Market Trends

The adoption of robotic-assisted physical rehabilitation technologies is fundamentally reshaping spasticity management by enabling high-intensity, repetitive gait training that manual therapy cannot sustain. Advanced exoskeletons are increasingly integrated into clinical practice to provide mechanical support and motor learning for patients with spinal cord injuries and neurological impairments. This shift towards automated rehabilitation is driven by improved reimbursement landscapes which have significantly expanded patient access to these premium devices. According to Lifeward Ltd., March 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', sales of the ReWalk Personal Exoskeleton increased by 130% in 2024, a growth trajectory directly attributed to established Medicare coverage facilitating broader commercial adoption.

Simultaneously, the proliferation of wearable neuromodulation and biofeedback devices is transitioning care from intermittent clinical visits to continuous, home-based mobility solutions. These non-invasive technologies, often designed as bionic clothing, utilize artificial intelligence to deliver functional electrical stimulation that corrects gait patterns and suppresses muscle spasms in real-time. The rapid market penetration of these user-friendly interfaces is evidenced by their expanding prescriber base. According to Cionic, September 2025, in the 'FDA Clears Cionic Neural Sleeve 2, Ushering in a New Era in Mobility Care', the company reported that its Neural Sleeve technology has reached 1,500 prescribers nationwide, highlighting the robust demand for adaptive, wearable therapeutic interventions.

Segmental Insights

The Online Pharmacies segment is recognized as the fastest-growing distribution channel in the Global Muscle Spasticity Market, primarily due to the convenience it offers to patients with limited mobility. Since muscle spasticity is often a chronic issue resulting from conditions like cerebral palsy or multiple sclerosis, the requirement for long-term medication adherence is critical. Online providers facilitate this through automated refills and direct home delivery, which mitigates the physical difficulties associated with frequent visits to brick-and-mortar stores. Additionally, the increasing utilization of digital prescriptions supports this trend, ensuring a streamlined supply chain for essential therapeutic drugs.

Regional Insights

North America maintains a dominant position in the Global Muscle Spasticity Market, primarily driven by a well-established healthcare infrastructure and a high prevalence of neurological disorders such as multiple sclerosis, cerebral palsy, and stroke. The region benefits from robust research and development initiatives led by key pharmaceutical companies, ensuring a steady pipeline of therapeutic options. Furthermore, regulatory bodies like the U.S. Food and Drug Administration (FDA) play a critical role in facilitating market growth through the approval of advanced treatments and label expansions. Comprehensive reimbursement policies also enhance patient access to these essential care solutions.

Recent Developments

• In July 2025, Bristol Myers Squibb initiated a global clinical trial to evaluate an investigational oral therapy, BMS-986368, for the treatment of spasticity in adults with multiple sclerosis. The Phase 2 study, known as BALANCE-MSS-1, aimed to enroll approximately 200 participants across multiple countries, including the United States, Australia, and Canada. The trial was designed to assess the safety and efficacy of the drug, which functions by inhibiting enzymes to boost endocannabinoid signaling and promote muscle relaxation. Study investigators highlighted the urgent need for effective oral treatments that offer better tolerability profiles than the currently available standard of care.
• In December 2024, Merz Therapeutics received approval from Health Canada for its neurotoxin, incobotulinumtoxinA, to treat post-stroke lower limb spasticity involving the ankle and foot in adults. This regulatory milestone expanded the product's label, which was previously authorized for upper limb spasticity, allowing healthcare providers to administer a combined total dose of up to 600 units for treating both upper and lower limbs. The Country Manager stated that this approval provides a comprehensive treatment option for stroke survivors dealing with equinovarus deformity and other spasticity-related mobility issues, significantly broadening the therapeutic scope for patients in the region.
• In October 2024, Saol Therapeutics released positive topline findings from its Phase 2 RAISE trial evaluating SL-1002 for limb spasticity. The study demonstrated that the novel chemoneurolytic injection met its primary safety endpoints and key secondary efficacy measures, including a statistically significant reduction in muscle tone as measured by the Modified Ashworth Score at six months. The Chief Executive Officer noted that the agent showed durability of effect, offering a potential new option for patients with debilitating spasticity. These results were presented at an international symposium, highlighting the progress of this investigational therapy in addressing unmet needs.
• In January 2024, Ipsen announced significant results from the AboLiSh study regarding the use of abobotulinumtoxinA for spasticity treatment. The data, presented at a major international toxin-focused conference, highlighted that patients treated with the company's neurotoxin using injection guidance techniques, such as ultrasound or electrical stimulation, were nearly three times more likely to achieve their treatment goals compared to those treated without such guidance. This observational study underscored the clinical value of precise administration in managing adult limb spasticity, reinforcing the company's commitment to improving patient outcomes and optimizing real-world practices within its neuroscience portfolio.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Novartis AG
• F. Hoffmann‑La Roche Ltd.
• Merck & Co., Inc.
• Eli Lilly and Company
• Bausch Health Companies Inc.
• Ipsen S.A.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

By Drug Type	By Route of Administration	By Distribution Channel	By Region
Baclofen Botulinum Toxin Diazepam Dantrolene Sodium Others	Oral Intramuscular Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Muscle Spasticity Market, By Drug Type:

• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Others

• Muscle Spasticity Market, By Route of Administration:

• Oral
• Intramuscular
• Others

• Muscle Spasticity Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Muscle Spasticity Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE